Cellectar Biosciences, Inc.

Description

• Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase I clinical study in patients with relapsed or refractory multiple myeloma. In addition, the company has initiated a Phase II clinical study to assess efficacy in a range of B-cell malignancies. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information please visit www.cellectar.com.
• 

  Headquarters:3301 Agriculture Dr , Florham Park, Wisconsin, United States

  More
• 

  Phone Number: +1 608-441-8120

• 

  Website: https://www.cellectar.com

• 

  Employees:15

• 

  Revenue:$10 - 50M

• 

  Legal Name:Cellectar Biosciences, Inc.

• Cellectar Biosciences, Inc.'s Social Media

  
• Is this data correct?

• |  NAICS Code: 325412  |

  Show More